bioRxiv Science⌕ Search

Biology subjects

Chiodetti, A. L.

Publications and source records attributed to Chiodetti, A. L..

2 recordsLinked to original sources

Transient immune landscape remodelling shapes CD8 T-cell priming during infection

Immune responses to intracellular pathogens require the generation of a CD8 T-cell response comprised of clones with a broad range of T Cell Receptor (TCR) affinities for their cognate peptide. While high-affinity clones clear pathogens during initial infection, low-affinity T-cells are critical to protect against subsequent encounters with mutated pathogens. Low-affinity T-cells are recruited to an immune response despite known mechanisms that limit their expansion and priming. As such, the mechanism safeguarding the recruitment of low-affinity T-cell clones during infection remains unclear. Here, we show that at the start of an infection, the spatial immune architecture is transiently reorganised to initiate broad T-cell priming. In particular, Tregs become segregated from the initial priming site, resulting in a spatio-temporal window during which pathogen-specific T-cell priming is protected from Treg inhibition. Priming induces the expression of CXCR3 in a TCR affinity-dependent manner, which conditions the retention of activated T-cells in the priming region. Inability to express CXCR3 leads to T-cell relocation towards Treg-rich areas, where their expansion is limited by the lack of the costimulatory molecule CD70. Our study redefines the role of Treg during infection and provides a mechanism to explain how the priming and breadth of the CD8 T-cell response is protected during infection.

immunology↗

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices

Tissue-targeted immunotherapies for type 1 diabetes (T1D) hold potential to protect pancreatic beta cells while minimizing systemic immunosuppression. We used a bispecific agonist called Immune Modulating Monoclonal-TCR Against Autoimmune Disease (ImmTAAI), consisting of a T cell receptor (TCR) targeting domain fused with a PD-1 agonist to specifically bind beta cells and suppress autoreactive T cells. We used live pancreas slices to demonstrate targeting of ImmTAAI molecules to pre-proinsulin peptide-HLA-A2 complexes on human beta cells. ImmTAAI protected beta cells from T cell killing by increasing T cell motility and inhibiting cytokine secretion. ImmTAAI treatment also increased the motility of islet-infiltrating T cells in slices from a donor with recent-onset T1D and preserved insulin secretion in slices co-cultured with T cell avatars transduced with diabetogenic TCRs. These data demonstrate that ImmTAAI molecules have the potential to limit T cell activity locally, making this an attractive platform to elicit targeted immunoregulation in T1D. One Sentence SummaryWe demonstrate inhibition of cellular immunity in human type 1 diabetes using a beta cell-targeting, affinity-enhanced TCR fused to a PD-1 agonist.

bioengineering↗